Table of Contents
NEW YORK — Forest Laboratories Inc. has shipped VIIBRYD tablets (vilazodone HCl), an antidepressant, to pharmacies throughout the United States.
The pharmaceutical company said Thursday that the Food and Drug Administration (FDA) approved VIIBRYD in late January, making the prescription drug the first and only approved selective serotonin reuptake inhibitor (SSRI) and 5HT1A receptor partial agonist.
VIIBRYD is indicated for the treatment of adults with major depressive disorder (MDD).
According to Forest, MDD annually affects more than 15 million U.S. adults, or about 6.5% of the nation’s adult population. People diagnosed with MDD show a combination of symptoms that interfere with their ability to work, sleep, study, eat and enjoy once-pleasurable activities. And despite the seriousness of the condition, nearly half of people with MDD don’t get treatment, the company said.
